Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05642455 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SPEARHEAD-3 Pediatric Study

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 11, 2026 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 5 of 10 sitesv12
  2. Lead sponsor: Adaptimmune to USWM CT, LLCv11
  3. Study sites: 11 to 10 Eligibility criteria expanded, about 71 words · Secondary endpoints: 9 to 8v10 Show 2 more changesShow less
    • Eligibility criteria expanded, about 71 words
    • Secondary endpoints: 9 to 8

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites revised (11)v9 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 2 of 11 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Site details revised at 2 of 11 sitesv7
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 12 to 11 · Start date changed from estimate of Oct 31, 2023 to Sep 1, 2023v6 Show 2 more changesShow less
    • Study sites: 12 to 11
    • Start date changed from estimate of Oct 31, 2023 to Sep 1, 2023
  3. Start date: Aug 30, 2023 to Oct 31, 2023 Site contacts updated at 1 of 12 sitesv5 Show 1 more changeShow less
    • Site contacts updated at 1 of 12 sites
  4. Study sites: 8 to 12v4
  5. Start date: Jun 30, 2023 to Aug 30, 2023 Completion date: Jun 30, 2038 to Jul 30, 2038v3 Show 1 more changeShow less
    • Completion date: Jun 30, 2038 to Jul 30, 2038
  6. Start date: May 1, 2023 to Jun 30, 2023 Primary endpoint revised · Study sites: 4 to 8 · Completion date: Apr 1, 2038 to Jun 30, 2038v2 Show 3 more changesShow less
    • Primary endpoint revised
    • Study sites: 4 to 8
    • Completion date: Apr 1, 2038 to Jun 30, 2038

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
USWM CT, LLC
8 trials monitored
See all monitored trials
Sarcoma
951 trials monitored
See 56 trials at risk
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Trial Details
NCT Number NCT05642455
Lead Sponsor USWM CT, LLC
Conditions Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov